Anika Therapeutics, Inc. (NASDAQ:ANIK – Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 528,900 shares, a growth of 13.0% from the October 15th total of 468,200 shares. Based on an average daily volume of 211,300 shares, the days-to-cover ratio is currently 2.5 days. Approximately 3.7% of the company’s shares are sold short.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on ANIK. Stephens reduced their price target on shares of Anika Therapeutics from $28.00 to $23.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 10th. StockNews.com assumed coverage on Anika Therapeutics in a research note on Thursday, October 5th. They set a “hold” rating on the stock. Finally, Barrington Research lifted their target price on Anika Therapeutics from $24.00 to $28.00 and gave the company an “outperform” rating in a research report on Friday, November 3rd.
Hedge Funds Weigh In On Anika Therapeutics
Anika Therapeutics Stock Performance
Shares of NASDAQ:ANIK traded down $0.05 during trading on Wednesday, hitting $21.02. The company’s stock had a trading volume of 3,935 shares, compared to its average volume of 118,972. Anika Therapeutics has a fifty-two week low of $16.54 and a fifty-two week high of $32.33. The business has a 50 day moving average price of $18.85 and a two-hundred day moving average price of $22.27.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally.
- Five stocks we like better than Anika Therapeutics
- What Are Meme Stocks and Are They Viable Investments?
- 5 must-have next-gen technologies that institutions are buying
- What Are Growth Stocks and Investing in Them
- 3 intriguing late-week earnings plays for short-term traders
- How to Invest in Virtual Reality
- Datadog is about to hit 52-week highs, and there’s more to come
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.